Elena Nikulina

Zevra Therapeutics details arimoclomol and miglustat study findings for rare disease event

Zevra Therapeutics details arimoclomol and miglustat study findings for rare disease event
Zevra Therapeutics targets rare disease

Zevra Therapeutics is set to present two encore posters at the SIMD2026 conference on May 18. The company will share results from the NPC002 clinical trial evaluating arimoclomol combined with miglustat and offer a genotype analysis of NPC1 from the U.S. expanded access program.

The presentations, scheduled between 7 and 9 PM, focus on Niemann-Pick disease type C (NPC), a rare genetic disorder. Zevra Therapeutics aims to advance the dialogue around treatment and genetic insights for this underserved rare disease community.

Zevra Therapeutics recently announced plans to report first quarter 2026 results with a live investor webcast on May 6. The upcoming update will provide stakeholders with a corporate overview. The company's presentations at SIMD2026 follow a series of scheduled disclosures and public communications.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.